It achieves this by interrupting EGFR signaling and halting the cell cycle at the G0/G1 phases, as well as by inhibiting VEGF, FAK (PTK2), MMPs, and Zxb1, all of which play roles in tumor development [238]. The gene discussed is PTK2; the disease is neoplasm.